Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L DeWall

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The AAPS Journal|January 30, 2020
Immunogenicity Risk Assessment for PEGylated TherapeuticsJohanna R Mora, Joleen T White, Stephen L DeWall
Plos One|March 23, 2021
Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 studyKaren Liao, Keguan Chen, Sara Brett, et al.
Journal of Immunological Methods|May 4, 2013
False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assayKeguan Chen, Jerry G Page, Ann M Schwartz, et al.
Plos One|March 2, 2016
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes MellitusElizabeth A McKie, Juliet L Reid, Prafull C Mistry, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The AAPS Journal|January 30, 2020
Immunogenicity Risk Assessment for PEGylated TherapeuticsJohanna R Mora, Joleen T White, Stephen L DeWall
Plos One|March 23, 2021
Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 studyKaren Liao, Keguan Chen, Sara Brett, et al.
Journal of Immunological Methods|May 4, 2013
False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assayKeguan Chen, Jerry G Page, Ann M Schwartz, et al.
Plos One|March 2, 2016
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes MellitusElizabeth A McKie, Juliet L Reid, Prafull C Mistry, et al.
Pageof 1